fruquintinib + placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Colorectal Cancer
Conditions
Colorectal Cancer
Trial Timeline
Dec 1, 2014 → Jan 17, 2017
NCT ID
NCT02314819About fruquintinib + placebo
fruquintinib + placebo is a phase 3 stage product being developed by HUTCHMED for Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02314819. Target conditions include Colorectal Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04322539 | Phase 3 | Completed |
| NCT02691299 | Phase 3 | Completed |
| NCT02314819 | Phase 3 | Completed |
| NCT02590965 | Phase 2 | Completed |
| NCT02196688 | Phase 2 | Completed |
Competing Products
20 competing products in Colorectal Cancer